For research and educational purposes only. Not intended for human consumption.
AOD-9604
Extensively Studied- •2025 meta-analysis of 6 RCTs
- •Discontinued research peptide status clarified
- •GRAS food additive status only
Advanced Obesity Drug | Modified hGH Fragment 176-191
Overview
What is AOD-9604?
AOD-9604 is a modified 17-amino acid fragment of human growth hormone (hGH 176-191) with an added N-terminal tyrosine. While early research showed fat loss potential without GH side effects, 2025 analyses classify it as a 'discontinued research peptide' with no FDA therapeutic approval. It has GRAS status for food additives only, and clinical translation remains stalled due to lack of standardized dosing protocols. Banned by WADA
Key Benefits
Stimulates fat loss through lipolysis without growth hormone side effects. Does not increase IGF-1, affect glucose metabolism, or cause insulin resistance. Meta-analysis of 6 RCTs confirms no effect on serum IGF-1. May support cartilage repair in combination protocols.
Mechanism of Action
AOD-9604 promotes fat metabolism through AMPK activation and lipid metabolism pathways, without binding to the GH receptor. Reduces visceral fat tissue through beta-3 adrenergic receptor upregulation while avoiding effects on glucose homeostasis or systemic IGF-1 levels.
Molecular Information
Pharmacokinetics
Research Indications
Fat Loss / Lipolysis
Primary research indication. Increases fat oxidation, plasma glycerol levels, and reduces body weight without affecting glucose metabolism.
Lipogenesis Inhibition
Reduces fat synthesis and storage in adipose tissue. Effects demonstrated in both animal models and human adipose tissue.
Metabolic Safety
Unlike full hGH, does not cause hyperglycemia, reduce insulin secretion, or increase insulin resistance.
Research Protocols
Disclaimer: Best administered in the morning on an empty stomach. Wait 30 minutes before eating. Some protocols suggest injection into abdominal subcutaneous fat.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Fat loss | 250-300mcg | Once daily | Subcutaneous |
| Enhanced fat loss | 400-500mcg | Once daily | Subcutaneous |
| Joint support | 250mcg | Once daily | Subcutaneous |
| Conservative start | 200mcg | Once daily | Subcutaneous |
Timing: Best administered in the morning on an empty stomach. Wait 30 minutes before eating. Some research protocols suggest injection into abdominal subcutaneous fat for localized effect.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Allow vial to reach room temperature (15-20 minutes)
Calculate required BAC water volume
Draw BAC water into syringe
Inject slowly down vial side (not directly onto powder)
Gently swirl until dissolved (never shake vigorously)
Store reconstituted solution at 2-8°C and use within 28 days
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
White Lyophilized Powder
Should appear as white to off-white powder or cake. Uniform appearance indicates proper freeze-drying.
Clear Solution After Reconstitution
When mixed with BAC water, solution should be crystal clear without particles.
Certificate of Analysis
Quality suppliers provide CoA showing purity >98% by HPLC.
No FDA Drug Approval
AOD-9604 has GRAS status for food use but is NOT approved as a therapeutic drug.
Discolored or Clumped Powder
Yellow discoloration or excessive clumping may indicate degradation.
WADA Prohibited
Banned by World Anti-Doping Agency. Athletes subject to testing must not use.
What to Expect
- •Week 1-2: Minimal noticeable effects, compound building in system
- •Week 3-4: May notice subtle changes in body composition
- •Week 5-8: More noticeable fat loss, especially with diet and exercise
- •Week 8-12: Continued fat reduction, improved body composition
- •Side effects: Generally well-tolerated, mild injection site reactions possible
Side Effects & Safety
Side Effects
- •Generally well-tolerated in clinical trials
- •Does not affect blood glucose or insulin - safer than full hGH
- •Does not increase IGF-1 levels
- •May cause mild injection site reactions
- •Not recommended during pregnancy or breastfeeding
- •WADA prohibited substance - not for competitive athletes
When to Stop
- •Signs of infection at injection site
- •Allergic reactions
- •Unusual symptoms
- •Before drug testing (WADA prohibited)
- •Consult healthcare provider
References
4 StudiesMeta-Analysis of RCTs for Visceral Fat (2025)
6 randomized controlled studies | Various doses | Significant visceral fat reduction
Meta-analysis confirmed AOD-9604 significantly reduces visceral adipose tissue with no effect on serum IGF-1 levels, distinguishing it from complete HGH therapy. Results typically seen after 12 weeks with diet and exercise.
View StudyDiscontinued Research Status (2025)
Regulatory/Research Analysis | Not an approved therapeutic
As of 2025, AOD-9604 is classified as a discontinued research peptide. Major barrier to clinical translation is lack of standardized dosing protocols across studies with wide variation in routes, doses, and durations.
Safety and GRAS Status
FDA/Clinical Evaluation | Very good safety profile
Multiple non-clinical studies show no genotoxicological or toxicological concerns. Received GRAS (Generally Recognized As Safe) status for food additives. Clinical evaluations describe safety 'indistinguishable from placebo'.
Quick Start Guide
Research Disclaimer
AOD-9604 is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving AOD-9604 must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of AOD-9604 for any purpose. Consult qualified professionals for any research applications.